Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Tamiflu Prevents Flu In More Than 99% Of Frail Elderly - ICAAC

Executive Summary

Prophylactic use of Roche's Tamiflu (oseltamivir) reduced the incidence of influenza in an elderly nursing home population to less than 1%, according to preliminary results from a once-daily prevention study presented by Frederick Hayden, MD, University of Virginia, Sept. 27 at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco.

You may also be interested in...



Gilead/Roche Tamiflu Has Two-Thirds Of Flu Market, Gilead Tells BIO

Tamiflu is garnering about two-thirds of U.S. neuraminidase inhibitor prescriptions as the 1999-2000 flu season winds down, Gilead CEO John Martin, PhD, said Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.

Gilead/Roche Tamiflu Has Two-Thirds Of Flu Market, Gilead Tells BIO

Tamiflu is garnering about two-thirds of U.S. neuraminidase inhibitor prescriptions as the 1999-2000 flu season winds down, Gilead CEO John Martin, PhD, said Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.

Roche Tamiflu Reduces Flu Symptom Severity 40% - Swiss Label

Roche's oral influenza therapy Tamiflu (oseltamivir) was associated with a 40% reduction in the severity of flu symptoms in patients with verified influenza compared to placebo, Swiss labeling reports.

Related Content

UsernamePublicRestriction

Register

PS034933

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel